GlassScriptPhysician profile
Tanya Castor
NPI 1326130451
$4,571.31
in general payments reported to CMS, 2019-2025
29 companies · $1,517 in 2025
The $1,517 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $820 · 2022: $976 · 2023: $598 · 2024: $661 · 2025: $1,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,625 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,625.41 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $997.99 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $818.94 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $692.60 | 2021-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $296.68 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $290.52 | 2022-2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $231.71 | 2021-2025 | |
| Genzyme Corporation | $183.78 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $101.65 | 2021-2025 | |
| United Therapeutics Corporation | $99.74 | 2021-2023 | Tyvaso |
| Genentech USA, INC. | $91.25 | 2022-2024 | Xolair |
| Insmed, INC. | $76.22 | 2025 | Arikayce |
| Philips North America LLC | $71.16 | 2025 | Encore, Patient Interface Software |
| Mylan Specialty L.P. | $60.66 | 2021-2023 | Yupelri |
| Aerin Medical INC. | $59.80 | 2022-2024 | |
| Abbott Laboratories | $59.52 | 2025 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $57.59 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $56.08 | 2021-2024 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $52.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.76 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.11 | 2021-2024 | |
| Csl Behring | $30.64 | 2024 | Kcentra |
| Intersect Ent, INC. | $26.28 | 2021 | |
| Pulmonx Corporation | $22.31 | 2022 | |
| Integra Lifesciences Corporation | $20.19 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Kerecis Limited | $19.64 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Apria Healthcare LLC | $16.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.20 | 2021 | |
| Tactile Systems Technology INC | $14.69 | 2022 | |
| Harmony Biosciences LLC | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Castor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.